Abstract
High-resolution peripheral quantitative computed tomography (HR-pQCT) is a noninvasive imaging modality for assessing volumetric bone mineral density (vBMD) and microarchitecture of cancellous and cortical bone. The objective was to (1) assess fracture-associated differences in HR-pQCT bone parameters; and (2) to determine if HR-pQCT is sufficiently precise to reliably detect these differences in individuals. We systematically identified 40 studies that used HR-pQCT (39/40 used XtremeCT scanners) to assess 1291 to 3253 and 3389 to 10,687 individuals with and without fractures, respectively, ranging in age from 10.9 to 84.7 years with no comorbid conditions. Parameters describing radial and tibial bone density, microarchitecture, and strength were extracted and percentage differences between fracture and control subjects were estimated using a random effects meta-analysis. An additional meta-analysis of short-term in vivo reproducibility of bone parameters assessed by XtremeCT was conducted to determine whether fracture-associated differences exceeded the least significant change (LSC) required to discern measured differences from precision error. Radial and tibial HR-pQCT parameters, including failure load, were significantly altered in fracture subjects, with differences ranging from −2.6% (95% confidence interval [CI] −3.4 to −1.9) in radial cortical vBMD to −12.6% (95% CI −15.0 to −10.3) in radial trabecular vBMD. Fracture-associated differences reported by prospective studies were consistent with those from retrospective studies, indicating that HR-pQCT can predict incident fracture. Assessment of study quality, heterogeneity, and publication biases verified the validity of these findings. Finally, we demonstrated that fracture-associated deficits in total and trabecular vBMD and certain tibial cortical parameters can be reliably discerned from HR-pQCT-related precision error and can be used to detect fracture-associated differences in individual patients. Although differences in other HR-pQCT measures, including failure load, were significantly associated with fracture, improved reproducibility is needed to ensure reliable individual cross-sectional screening and longitudinal monitoring. In conclusion, our study supports the use of HR-pQCT in clinical fracture prediction.
| Original language | English |
|---|---|
| Pages (from-to) | 446-459 |
| Number of pages | 14 |
| Journal | Journal of Bone and Mineral Research |
| Volume | 35 |
| Issue number | 3 |
| Early online date | 23 Oct 2019 |
| DOIs | |
| Publication status | Published - Mar 2020 |
Funding
This study was supported by the Mereo BioPharma Group. Authors' roles: Conceptualization: AH. Methodology: KW, MMB, NM, SVK, and AH. Data collection: MMB, KW, and NM. Formal analysis: MMB, KW, NM, and SVK. Interpretation: NM, NB, AJB, LF, AH, KMK, PTL, ACO, JS, BvR, SNM, BMW, SVK, FHG, and DL. Manuscript preparation: MMB, KW, NM, and SVK. All authors contributed to the critical revision and approval of the final manuscript. A This study was supported by the Mereo BioPharma Group. Authors' roles: Conceptualization: AH. Methodology: KW, MMB, NM, SVK, and AH. Data collection: MMB, KW, and NM. Formal analysis: MMB, KW, NM, and SVK. Interpretation: NM, NB, AJB, LF, AH, KMK, PTL, ACO, JS, BvR, SNM, BMW, SVK, FHG, and DL. Manuscript preparation: MMB, KW, NM, and SVK. All authors contributed to the critical revision and approval of the final manuscript. ACO has received grant funding from Alexion and honoraria from Alexion, BioMarin, and Infomed. AJB has received institutional research support from Ultragenyx. BMW is a consultant for Mereo BioPharma and has received research grants from Mereo BioPharma. BvR is a consultant for Scanco Medical AG. FHG is a consultant to Amgen, Mereo BioPharma, and Novartis, and has received research grants from Amgen and Mereo BioPharma. KMK has received institutional research support and materials from Mereo BioPharma, research materials from Amgen and UCB Pharma, and institutional research support from Cayman Chemical for unrelated studies. KW is an employee of Oxford PharmaGenesis, which received funding to conduct this systematic review, and for medical writing support, from Mereo Biopharma. MMB is an independent contractor for Oxford PharmaGenesis, which received funding to conduct this systematic review, and for medical writing support, from Mereo Biopharma. NB has received grant funding from Alexion, Amgen, and Biomarin, honoraria from Alexion, Kyowa Kirin, and Mereo BioPharma, and is a consultant for Mereo BioPharma and UCB. PTL is an independent consultant to various biotech and academics, including Mereo BioPharma. SNM has received research grants paid to the research institution by Amgen and Merck.
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- ANALYSIS
- QUANTITATION OF BONE
- BONE QCT
- CLINICAL TRIALS
- FRACTURE RISK ASSESSMENT
- STATISTICAL METHODS
- ANALYSIS/QUANTITATION OF BONE
Fingerprint
Dive into the research topics of 'HR-pQCT measures of bone microarchitecture predict fracture: systematic review and meta-analysis'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver